NCT07148180: A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 31 planned
- Started
- 2 Feb 2026
- Primary completion
- 31 Dec 2028
- Arms
- Arm 1: Phase 1 Dose Escalation, Arm 2: Phase 2 Dose Expansion
- Results
- None posted
- 29 Aug 2025: Trial registered
- 2 Feb 2026: Trial started